Panobinostat (LBH589)

目录号:S1030 别名: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Phase 3。

规格 价格 库存 购买数量  
RMB 731.86 现货
RMB 2189.52 现货
RMB 5485.18 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献216篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Phase 3。
靶点
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外研究

LBH589诱导MOLT-4和Reh细胞凋亡,这种作用具有时间和剂量依赖性。而且,LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长,处理48小时,具有剂量依赖性。与对照组细胞相比,用LBH589处理的细胞,在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关,LBH589也降低c-Myc的表达水平,具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589(10 nM)处理Reh细胞,最初增强c-Myc的表达水平,之后一直降低c-Myc的表达水平。此外,LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下,LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。[1]此外, LBH589抑制非小细胞肺癌细胞系生长,如人类H1299,L55和A549,IC50分别为5,11和30 nM;间皮瘤细胞生长,如人类OK-6和 Ok-5,IC50分别为5和7 nM;及小细胞肺癌细胞系生长,如人类RG-1和LD-T,IC50分别为4和5 nM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NXfTO|luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP3NE0yOCEQvF2= M4TZelAuPCCm NH3HXGtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWHI[mdrOjZ5MEK3PFQ>
HepG2 NH3jPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6wMVExKM7:TR?= MUGwMVQh\A>? NHXsUGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{XqO|I3PzB{N{i0
HT29 MmThSpVv[3Srb36gRZN{[Xl? NF;iNo02OMLibl2= M3eyUlI1NTd{IHi= NFHvRnRqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDR6wrDoxsA> NITQbFAzPjdyMke4OC=>
HepG2 MV\GeY5kfGmxbjDBd5NigQ>? MXq1NOKhdk1? NUH2NZI{OjRvN{KgbC=> NV32ZmZmcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh NVm1RZRrOjZ5MEK3PFQ>
HCC827 M2LqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO5OoE2NzdwNT:xNEBvVQ>? NVHCdYV2PzMEoHi= MV\EUXNQ NXz1eYh1\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MYKyOlY4PTR6NB?=
A549  NIj4d3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNE8yPS9{MDDuUS=> M2jyVlczyqCq M1vUXmROW09? M{nvVIVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk MWCyOlY4PTR6NB?=
NCI-H460  M4HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOxZZlGOTBxMkCvN|Ahdk1? MnvjO|LDqGh? NHHFco9FVVOR MXLlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NU\qbHc5OjZ4N{W0PFQ>
J89GFP NEfpfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XtTGROW00EoB?= NULERmRFTUN3ME20PU45PSEEsTCxNk43PSCwTR?= MnTZNlY2PjN3Nki=
THP89GFP NYPz[nZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L5dGROW00EoB?= M3K2W2VEPTB;MUmuN|QhyrFiNj60N{BvVQ>? MUSyOlU3OzV4OB?=
SK-NEP-1 M3LPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vsWFAvODIkgKOxNE4xKM7:TR?= NWe3[294OjRiaB?= MXfEUXNQyqB? NEXYcnZKSzVyPUe2MlM1KG6P NUjUTVRNOjZzN{[yNVk>
G401 NUGyVpVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCwMlAy6oDVMUCuNEDPxE1? MkTpNlQhcA>? NHfBRphFVVORwrC= M33QWWlEPTB;MUSzMlAzKG6P NH2ySHIzPjF5NkKxPS=>
SK-NEP-1 NFXnXFNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3S2flUxKG6P MW[x5qCUPCCm NWDxOXNxTE2VT9Mg MnPJdoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MVyyOlE4PjJzOR?=
G401 MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmjmOVAhdk1? NW\hNHdkOeLCk{Sg[C=> NYDkWZo{TE2VT9Mg NV7p[41TemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ M17Kd|I3OTd4MkG5
SK-NEP-1 MlSxRZBweHSxc3nzJGF{e2G7 MWe1NE8yODBibl2= MXuyOEBp MmHBSG1UV8Li MmrDbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlSyNlYyPzZ{MUm=
G401 MmqzRZBweHSxc3nzJGF{e2G7 M4HsbVUxNzFyMDDuUS=> M{XkPFI1KGh? Mo\YSG1UV8Li MYfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MorYNlYyPzZ{MUm=
SK-NEP-1 MUfGeY5kfGmxbjDBd5NigQ>? NYjQOHdGPTBxMUCwJI5O NHfKSGszPCCq NFHnb2xFVVORwrC= M3fOdZNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NVT5Woo4OjZzN{[yNVk>
G401 MVfGeY5kfGmxbjDBd5NigQ>? MVK1NE8yODBibl2= MmfYNlQhcA>? NW\SWZV1TE2VT9Mg M1nhcpNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NUPYfnNMOjZzN{[yNVk>
SK-NEP-1 MV3GeY5kfGmxbjDBd5NigQ>? Ml\4OVAwOTByIH7N NVzHUHhvOjRiaB?= NGq0clBFVVORwrC= MV7pcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> MlrlNlYyPzZ{MUm=
G401 M2TzdmZ2dmO2aX;uJGF{e2G7 NFPaTHM2OC9zMECgcm0> MlHmNlQhcA>? M3HTeGROW00EoB?= NF\GdmRqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? MlHxNlYyPzZ{MUm=
RPMI 8226 NV33UolMS2WubDDTeZJ3cX[jbDDBd5NigQ>? NVzJdGN2Oi92L{[gcm0> MoXlOFjjiImq Mn;WbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? M1\IWVI3ODByMkmy
OPM2 MWDD[YxtKFO3co\peoFtKEG|c3H5 MnK5Nk81NzZibl2= MnnDOFjjiImq NYjqTmxScW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= M37YVFI3ODByMkmy
U266 MX\D[YxtKFO3co\peoFtKEG|c3H5 NUHzd3pPOi92L{[gcm0> MUO0PQKBkWh? MX\pcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MmTRNlYxODB{OUK=
H929 MUHD[YxtKFO3co\peoFtKEG|c3H5 M2rXeFIwPC94IH7N NITxTYk1QOLCiXi= M4\VNolv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MojFNlYxODB{OUK=
RPMI 8226  NGrQfWJCeG:ydH;zbZMhSXO|YYm= MV605qCKdk1? M4HOdlI1NzR6IHi= NX7nU|Z2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NVnMcWFzOjZyMECyPVI>
HCC827 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;5TVEyOCCwTR?= NWX5OmhiPDhiaB?= NHz1R5pFVVOR NVzScllv\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= NH\Pe5kzPTl2NE[xOy=>
NCI-H23 M3f4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[xNEBvVQ>? MoroOFghcA>? NYLHUXcyTE2VTx?= MUTlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? NVzybZhKOjV7NES2NVc>
AML3 M1zLeGZ2dmO2aX;uJGF{e2G7 M2TqNFAuOSEQvF2= MoDVNlTDqGh? M3u4cIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYfp[HRROjV4MUK5OFE>
ML-1 NF;yXmtHfW6ldHnvckBCe3OjeR?= NIL0UZoxNTFizszN MmLGNlTDqGh? MlOxbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWGyOVYyOjl2MR?=
RPMI-8226vr10  NHvjVVhHfW6ldHnvckBCe3OjeR?= MmfaNE0yKM7:TR?= NEe3[5kzPMLiaB?= NXG1ZnFpcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYrBb2FDOjV4MUK5OFE>
ML-1 M3fVZ2Z2dmO2aX;uJGF{e2G7 Mn7yNUDPxE1? NWmyVIhbOjUEoHi= NVPjOFZwcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ> M1v4NlI2PjF{OUSx
RPMI-8226vr10  Ml3ZSpVv[3Srb36gRZN{[Xl? M4nENVEh|ryP M2e1VlI1yqCq NH7aWHBqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl MWCyOVYyOjl2MR?=
SK-N-BE (2) MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjwfJczPOLCiXi= NX7JPWI1UUN3ME2xNFQvOOLCidMx5qCKPy56IH7N MXGyOVMxQDlzNh?=
SK-N-BE (2), PAN  MK M2PqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\oNlTjiImq NGqwbnZKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= M4LDclI2OzB6OUG2
SK-N-BE (2), MK  PAN NIDmcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXKdml6OjUkgJno M1O0OmlEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2= NGSzPHUzPTNyOEmxOi=>
SK-N-AS NYe0Oll4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;lNlTjiImq NVHqPYhDUUN3ME2zO{4y6oDLwsJihKkzNjRibl2= Mn;wNlU{ODh7MU[=
SK-N-DZ MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HrNlI16oDLaB?= MnPXTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? MXOyOVMxQDlzNh?=
Caki-1 NX3WT4h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:xNE8zPS93MDDuUS=> M120VlQ5KGh? NI\JNGJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MYWyOVI4QTF7MR?=
ACHN NHPldWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m3Z|ExNzJ3L{WwJI5O NGS3dpY1QCCq M4PoOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NEfXVGIzPTJ5OUG5NS=>
769-P NH\EUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDjb3QyOC9{NT:1NEBvVQ>? MoSzOFghcA>? NGnuOmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MnflNlUzPzlzOUG=
786-O  Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[wdlExNzJ3L{WwJI5O NFvK[Yw1QCCq MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MYWyOVI4QTF7MR?=
Caki-1 MnfMRZBweHSxc3nzJGF{e2G7 NYK2T4tLPTBibl2= MljVOFghcA>? MmnybY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? Mm\jNlUzPzlzOUG=
ACHN NXHYW|N3SXCxcITvd4l{KEG|c3H5 NUnDZZlCPTBibl2= NU\IdJUyPDhiaB?= NX73fJlocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MlfZNlUzPzlzOUG=
769-P MUTBdI9xfG:|aYOgRZN{[Xl? NHLqXY82OCCwTR?= NGCxSYY1QCCq MYXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? NY\LZnhoOjV{N{mxPVE>
786-O  NGC2Ro9CeG:ydH;zbZMhSXO|YYm= MVK1NEBvVQ>? M1nyN|Q5KGh? Ml3RbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? NVnBRWFVOjV{N{mxPVE>
Caki-1 NGjRTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M125clI2NzVyIH7N M2TpRlQ5KGh? NVPGUJBXTE2VTx?= Ml;VbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= NUW2dlB1OjVzN{[zOVQ>
ACHN NFvoNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV24O4xqOjVxNUCgcm0> MYm0PEBp MlSySG1UVw>? M1jkbolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= MormNlUyPzZ|NUS=
769-P M{\BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfqWI8zPS93MDDuUS=> MUK0PEBp NYjaVXgyTE2VTx?= NGfBU|dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NIHQe3kzPTF5NkO1OC=>
Caki-1 MonMR49td267IF\vdo1ifGmxbjDBd5NigQ>? NV7LSJg{PTBibl2= MW[3MVE1KGR? M3S2fGROW09? MYTzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MVyyOVE4PjN3NB?=
ACHN NHHvbWVEd2yxbomgSo9zdWG2aX;uJGF{e2G7 NV\hSFh2PTBibl2= NGPIcIo4NTF2IHS= NXH5TJdnTE2VTx?= NXnDWY96e3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? Mn7xNlUyPzZ|NUS=
769-P NFrseJZEd2yxbomgSo9zdWG2aX;uJGF{e2G7 NHHRXJU2OCCwTR?= MV:3MVE1KGR? M1SzXmROW09? NIDH[2l{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? M2jkSlI2OTd4M{W0
Caki-1 M4HtfGFxd3C2b4Ppd{BCe3OjeR?= M1jpZ|UxKG6P M2mzS|Q5KGh? NH[wZWNFVVOR M3XKS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFnYTXkzPTF5NkO1OC=>
ACHN MVHBdI9xfG:|aYOgRZN{[Xl? M2nHZVUxKG6P MmXqOFghcA>? MoXYSG1UVw>? NHXIc2tqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NH25foczPTF5NkO1OC=>
769-P M{XYWmFxd3C2b4Ppd{BCe3OjeR?= MXK1NEBvVQ>? MkexOFghcA>? M1\VXmROW09? MojLbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlLwNlUyPzZ|NUS=
MDA-MB-231 NFXlVYNOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? M1HQXVExyqCwTR?= MoDQN:Kh\A>? M2T6XGROW09? MWfhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? MVWyOFgyODR7Nx?=
BT-549 NImzVJFOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? M{XP[lExyqCwTR?= MVuzxsBl MlLnSG1UVw>? M2HGUYFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= MXKyOFgyODR7Nx?=
MCF-7  NGXKVm1Od3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? NYrBUHVqOTEEoH7N M3Tvb|PDqGR? NX3oV2Z[TE2VTx?= NYrUWXpm[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg NHXi[nEzPDhzMES5Oy=>
MCF-7 M3PyS2Z2dmO2aX;uJGF{e2G7 MUS1MVUxKG6P MmnTNlQhcA>? NWHReYJHTE2VTx?= NGPQOXlz\WS3Y3XkJJRp\SCuZY\lcEBw\iCneIDy[ZN{cW:wIH;mJGVT|rFuIGDSJIFv\CCIb4jBNeKh MkHHNlQ{PjZ2MEe=
CTS MorvRZBweHSxc3nzJGF{e2G7 MXyw5qCUPDBibl5CpC=> MWW0PEBp NV;O[VBFcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVvj[ZV6OjR{NES0Nlk>
OCI-AML3  NHrJPJlCeG:ydH;zbZMhSXO|YYm= M1zub|DjiJN2MDDuUeKh Mn3oOFghcA>? Mnf2bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Ml3lNlQzPDR2Mkm=
U937 MlPRRZBweHSxc3nzJGF{e2G7 NVfjUGxXOOLCk{SwJI5OyqB? MVW0PEBp NU\Eb2hFcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIfWfJQzPDJ2NESyPS=>
PC3 M2jrTWFxd3C2b4Ppd{BCe3OjeR?= NUTBT|FNOC1zMECgcm0> MWGyOE81QCCq M2nMdolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MV[yOFE3OzJ|MB?=
PC3-AR M2DYeWFxd3C2b4Ppd{BCe3OjeR?= M2TmRVAuOTByIH7N MWSyOE81QCCq NHL3TlJqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NESwfG0zPDF4M{KzNC=>
PC3 M3\4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTlN3REOC1zMECgcm0> M2DoUVI1NzR6IHi= MofrbY5lfWOnczDhZ4N2dXWuYYTpc44hd2Zic4XiS|EheG:ydXzheIlwdg>? MonYNlQyPjN{M{C=
PC3-AR NUK5bHNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHVPJZJOC1zMECgcm0> M3ToflI1NzR6IHi= M1vJUolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= MUSyOFE3OzJ|MB?=
PC3 Mmq2SpVv[3Srb36gRZN{[Xl? MmjyNE0yODBibl2= NGiydZYzPCCq MWLzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= MUGyOFE3OzJ|MB?=
PC3-AR M{jpWGZ2dmO2aX;uJGF{e2G7 MoPrNE0yODBibl2= M2e2dlI1KGh? NV;hS3Jqe3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> M325b|I1OTZ|MkOw
OS-RC-2 MnH6R4VtdCCYaXHibYxqfHliQYPzZZk> M3rTfFAuOTByMDDuUS=> Mn7kNlQwPDhxN{KgbC=> M2XXb2ROW09? MnXO[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYf0e5U3OjRzNES3N|c>
OS-RC-2 NFzKd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX5XFV2PTBibl2= Mnn6OFghcA>? MUXEUXNQ MlPFbY5lfWOnczDHNk9OKGG{cnXzeC=> Mk\0NlQyPDR5M{e=
OS-RC-2 M1HPRmFxd3C2b4Ppd{BCe3OjeR?= M4LyZlUxKG6P MmnxOFghcA>? MWrEUXNQ MWLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NI\wVFIzPDF2NEezOy=>
SK-N-AS NUXXfYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;aNQKBmzhyIH7N MnrjOFghcA>? Mo\lTWM2OD1{Nz60JI5O Mk\pNlQxQTh5OUm=
SK-N-DZ Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn1PVJVOOLCk{iwJI5O M2XMXFQ5KGh? M1mweGlEPTB;MkGuPUBvVQ>? MX2yOFA6QDd7OR?=
SK-N-SH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HFZVDjiJN6MDDuUS=> MWi0PEBp Mlz6TWM2OD15Mj6zJI5O MnXCNlQxQTh5OUm=
SK-N-BE M{DlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSwRVMx6oDVOECgcm0> NWLmUnN7PDhiaB?= M374ZmlEPTB;N{WuOEBvVQ>? Mn;uNlQxQTh5OUm=
SK-N-AS MXzBdI9xfG:|aYOgRZN{[Xl? MWOw5qCUQDBibl2= M1HxVlQ5KGh? M3fWVZBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NF\NcnkzPDB7OEe5PS=>
SK-N-DZ NFTCUZZCeG:ydH;zbZMhSXO|YYm= MmL1NQKBmzhyIH7N MY[0PEBp NIr1RVJxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NVH0TWdqOjRyOUi3PVk>
SK-N-SH NXPXeppYSXCxcITvd4l{KEG|c3H5 NV;h[pRrOOLCk{SwJI5O MmewOFghcA>? NGKwTZNxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MYSyOFA6QDd7OR?=
SK-N-BE NF7mOmFCeG:ydH;zbZMhSXO|YYm= NETweHox6oDVNECgcm0> NU\0cWpSPDhiaB?= MVHwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= M3r3SlI1ODl6N{m5
SK-N-AS MUXGeY5kfGmxbjDBd5NigQ>? M{HtblDjiJN6MDDuUS=> MkfEOFghcA>? MWnpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ MV[yOFA6QDd7OR?=
SK-N-DZ MVLGeY5kfGmxbjDBd5NigQ>? MXyw5qCUQDBibl2= NIPOepk1QCCq NWDhNWF2cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MlvENlQxQTh5OUm=
SK-N-SH MYXGeY5kfGmxbjDBd5NigQ>? MYmw5qCUPDBibl2= NVLmb5ROPDhiaB?= MlXCbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MlHQNlQxQTh5OUm=
SK-N-BE MW\GeY5kfGmxbjDBd5NigQ>? M37H[FDjiJN2MDDuUS=> NWrNRWl7PDhiaB?= MkX0bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NHf0S|kzPDB7OEe5PS=>
HCC-LM3 M2DRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxMVExODBibl2= NFviV5czPC92OD:3NkBp MlOzSG1UVw>? NHLteVJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3nCO|I1ODl|OUW2
HepG2 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnZS2dVOS1zMECwJI5O NYLrcHpsOjRxNEivO|IhcA>? NYLzOnhbTE2VTx?= M4nIUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3\DTFI1ODl|OUW2
SMMC-7721 NWexdYZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPaSZcyNTFyMECgcm0> MWWyOE81QC95MjDo M4jsdGROW09? NGfoNIhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYmyOFA6Ozl3Nh?=
HCC-LM3 MmTwRZBweHSxc3nzJGF{e2G7 NGfNcXM2OCCwTR?= NXvMVpZOPDhiaB?= Mne2SG1UVw>? NI\yV2FqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? MUKyOFA6Ozl3Nh?=
HepG2 NFnnZohCeG:ydH;zbZMhSXO|YYm= NX7oZnZ5PTBibl2= NFrq[Ys1QCCq NYTvfIZuTE2VTx?= NGPqO2RqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? MUGyOFA6Ozl3Nh?=
SMMC-7721 NUDwcYczSXCxcITvd4l{KEG|c3H5 NY[xZZhjPTBibl2= Mn7uOFghcA>? MYfEUXNQ MkXvbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> MkfINlQxQTN7NU[=
HCC-LM3 NYPKWVZiTnWwY4Tpc44hSXO|YYm= MmjMOVAwOTByIH7N NFLTe2MzPCCq NFfiTplFVVOR M3LnfYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= NH;ObWszPDB7M{m1Oi=>
HepG2 NG\VNVNHfW6ldHnvckBCe3OjeR?= M3\LOFUxNzFyMDDuUS=> M3TTNlI1KGh? NYfHfXBOTE2VTx?= M3j5SoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= NWi1bWg4OjRyOUO5OVY>
SMMC-7721 M3yzXmZ2dmO2aX;uJGF{e2G7 NF;WXHI2OC9zMECgcm0> NELXXJIzPCCq NF7lUHlFVVOR MnPq[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= NVHYV5JUOjRyOUO5OVY>
HCC-LM3 NV;GWXlITnWwY4Tpc44hSXO|YYm= NFS0TmM2OC9zMECgcm0> NUKzVI1ROjRiaB?= NGO3SJpFVVOR MU\kc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MnSzNlQxQTN7NU[=
HepG2 M2\UeGZ2dmO2aX;uJGF{e2G7 NXHzdI91PTBxMUCwJI5O MYKyOEBp M17NfWROW09? MXTkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v M2nZVVI1ODl|OUW2
SMMC-7721 MY\GeY5kfGmxbjDBd5NigQ>? MkX1OVAwOTByIH7N NYrQXXBUOjRiaB?= Mmq5SG1UVw>? NXziOm9k\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NVr0ZmhFOjRyOUO5OVY>
FaDu MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XueVExOOLChX7N NIP0R5g5NzFyL{GyJIg> MlfC[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:|dDDy[Yxm[XOn M4DyPVI1ODJ4NEiy
FaDu M4PCcWZ2dmO2aX;uJGF{e2G7 NVfaZlFLOTBy4pEFcm0> MofKNk81NzhxMUKgbC=> MoCwbY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25? NHizbFQzPDB{NkS4Ni=>
PC-3  MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17XblAuOTBizszN MWqyOE81QC95MjDo NYHrN4p2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWeyN|k6OTJzNh?=
LNCaP NGSybWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljDNE02KM7:TR?= NYXpTINSOjRxNEivO|IhcA>? MoHwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHvROG8zOzl7MUKxOi=>
RWPE-1  M17K[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rOclAuOjBizszN MXqyOE81QC95MjDo MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVKyN|k6OTJzNh?=
Capan-1 NHHseHFHfW6ldHnvckBCe3OjeR?= M3\0TlI2NzVyL{GwNEBvVQ>? MUe4M|I1NzR6IHi= NFfqclZFVVOR NFX1NXVld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n MUWyN|kzOjh6Nh?=
L3.6pl MofkSpVv[3Srb36gRZN{[Xl? MV:yOU82OC9zMECgcm0> Ml:wPE8zPC92ODDo NIC3N|hFVVOR M3fze4Rwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= NVXKTWdIOjN7MkK4PFY>
CFPAC-1  MmHrSpVv[3Srb36gRZN{[Xl? M37h[|I2NzVyL{GwNEBvVQ>? MoLjPE8zPC92ODDo MVrEUXNQ Mn\p[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= M1zJdlI{QTJ{OEi2
Capan-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPNRnAzPS93MD:xNFAhdk1? NXXqOFdrPDhiaB?= NEj1dmJFVVOR MlfudoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmPzNlM6OjJ6OE[=
L3.6pl NY\ZPHNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTTVJVDOjVxNUCvNVAxKG6P NUPnTWxSPDhiaB?= NI\FWmpFVVOR NEHZbYdz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3HWO|I{QTJ{OEi2
CFPAC-1  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;mdJRHOjVxNUCvNVAxKG6P M1TOWVQ5KGh? NWnYT4lyTE2VTx?= Ml31doVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4D0NFI{QTJ{OEi2
Capan-1 NYjQcGFMSXCxcITvd4l{KEG|c3H5 Ml\QNlUwPTBxMUCwJI5O M2S1cFQ5KGh? NHT2S5BFVVOR MmTXbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX6yN|kzOjh6Nh?=
L3.6pl MnzmRZBweHSxc3nzJGF{e2G7 MUKyOU82OC9zMECgcm0> M2LHPFQ5KGh? NWWzUng2TE2VTx?= MYPpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXWyN|kzOjh6Nh?=
CFPAC-1  MWrBdI9xfG:|aYOgRZN{[Xl? M{nNWFI2NzVyL{GwNEBvVQ>? M2m4clQ5KGh? Mo\hSG1UVw>? NVq0RYhtcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M37ib|I{QTJ{OEi2
HN22 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHQNE0zOCCwTR?= MVuyOE81QCCq M3jPRWROW09? NYXveZVYcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NYf5dY81OjN6N{eyN|U>
HSC4  NWnvPI1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[2ZVAuOjBibl2= MnKxNlQwPDhiaB?= M{jybGROW09? M{XNcolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NGDWS4ozOzh5N{KzOS=>
HN22 MnrGRZBweHSxc3nzJGF{e2G7 M1vVWVAuOjBibl2= NYXEVGNtPDhiaB?= MonCSG1UVw>? Mln0bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVSyN|g4PzJ|NR?=
HSC4  NWDDR4tjSXCxcITvd4l{KEG|c3H5 MYGwMVIxKG6P NEjmWno1QCCq NGDCSGZFVVOR NUm0bpo{cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3rYTlI{QDd5MkO1
HN22 M3;Bbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Lmd|AuOjBibl2= M37KU|Q5KGh? MX\EUXNQ MofybY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg MUGyN|g4PzJ|NR?=
HSC4  NGOxdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2yUJRnOC1{MDDuUS=> MoTLOFghcA>? MX7EUXNQ MmG1bY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg Mo\LNlM5Pzd{M{W=
HN22 NFHpXXRHfW6ldHnvckBCe3OjeR?= NH;LNpcxNTJyIH7N MVy0PEBp Mmi5SG1UVw>? MmG3d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg NFrDWXkzOzh5N{KzOS=>
HSC4  MXvGeY5kfGmxbjDBd5NigQ>? M2HZe|AuOjBibl2= MVm0PEBp NW[5ZWdtTE2VTx?= Mnq5d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg NWfseWl{OjN6N{eyN|U>
Cal62 NYXsfGN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN|INMxJFQhdk1? M{O1[FI{QDJ2ME[0
Hth7 M175RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ThTWlEPTB;MUWgxtEhOiCwTR?= MnHWNlM5OjRyNkS=
Hth83 NIftSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN2INMxJFUhdk1? MUSyN|gzPDB4NB?=
C643 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPlbZBzUUN3ME23NUDDuSBzMDDuUS=> M{PDOlI{QDJ2ME[0
SW1736 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTnb|NrUUN3ME2zOUDDuSB6IH7N M{TBfVI{QDJ2ME[0
T241 NVr3Z4d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfNVVdKSzVyPU[1JOKyKDdibl2= MmLDNlM5OjRyNkS=
T351 NU\YTFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnITWM2OD13MDFCtUAyOCCwTR?= NIPYeHUzOzh{NEC2OC=>
BHP2-7 M4nsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vzfmlEPTB;M{egxtEhPiCwTR?= NFPIPXAzOzh{NEC2OC=>
T238 NYrJN5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;3dXNKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? Ml;MNlM5OjRyNkS=
HCT8 NWf5VZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGy[4RNPzJiaB?= NXThUoROTE2VTx?= NEXQVXlKSzVyPUGyMlnjiIoEsfMAjVEvQSCwTR?= MnfINlMzQTl|OEi=
H630 M4C5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV63NkBp M2\rb2ROW09? M2PhR2lEPTB;MUKuOQKBkcLz4pEJN{4yKG6P NFHJUXozOzJ7OUO4PC=>
cH630 5-FU-res M1e1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LsN|czKGh? MlWxSG1UVw>? M1zPSGlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P NX\MU3JQOjN{OUmzPFg>
HCT116 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfKeZB2PzJiaB?= NVvvNXZUTE2VTx?= MXTJR|UxRTFyLkhihKnDueLCiUKuNkBvVQ>? MVqyN|I6QTN6OB?=
HCT116 p53−/− M{TPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHq[YU4OiCq MmfDSG1UVw>? NVHsTnZTUUN3ME24MlbjiIoEsfMAjVEvPyCwTR?= MnvSNlMzQTl|OEi=
dHCT116 p21−/− NHT5WWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTaO|IhcA>? MkT2SG1UVw>? MYrJR|UxRTVwOfMAjeKy6oDLMT6zJI5O NFLWbJAzOzJ7OUO4PC=>
HT29 NWLXSIRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXDcJJ6PzJiaB?= NXfC[2h5TE2VTx?= MW\JR|UxRTF4LkRihKnDueLCiUKuN{BvVQ>? NFi3Oo0zOzJ7OUO4PC=>
LoVo NXziSIxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Qe5A4OiCq NXi0fGFuTE2VTx?= NXX1ZWxGUUN3ME21MlHjiIoEsfMAjVAvPiCwTR?= MWiyN|I6QTN6OB?=
RKO NVPJPZVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC3NkBp NYH4SY9QTE2VTx?= NIixS5ZKSzVyPUeuPgKBkcLz4pEJNk4zKG6P NH3ndHIzOzJ7OUO4PC=>
SW480 NXrRT5h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7MfXZCPzJiaB?= Mne1SG1UVw>? MVjJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? M3ztfFI{Ojl7M{i4
eSW620 M17FdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPqO|IhcA>? Mlq5SG1UVw>? NH\YbHhKSzVyPUmuNgKBkcLz4pEJNk4yKG6P MWSyN|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
体内研究 LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长,与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多,说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射,每周持续5天,导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比,LBH589作用于H526衍生的肿瘤下降53%,作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%,作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下,LBH589 作用于NSCLC和Meso衍生的移植瘤,导致SCLC衍生的肿瘤中有两种衰退,伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm3降低到实验结束时的116 mm3,RG-1衍生的平均肿瘤尺寸从实验开始时的185mm3降低到实验结束时的86 mm3[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: MOLT-4细胞和Reh(前体B细胞)
  • Concentrations: 50 nM
  • Incubation Time: 48小时
  • Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色,然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×104个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比,根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 携带10×106个M30细胞或5×106个A549细胞的SCID鼠
  • Formulation: 溶于水的5%葡萄糖
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 349.43
化学式

C21H23N3O2

CAS号 404950-80-7
储存条件 粉状
溶于溶剂
别名 NVP-LBH589

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT03515915 Recruiting -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Panobinostat (LBH589) | Panobinostat (LBH589)供应商 | 采购Panobinostat (LBH589) | Panobinostat (LBH589)价格 | Panobinostat (LBH589)生产 | 订购Panobinostat (LBH589) | Panobinostat (LBH589)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID